State of the GLP-1 market: August 2026

The month in one paragraph

August's story is a falling floor and a widening honesty gap. The lowest independently reported compounded tirzepatide price dropped to $119–129/month flat (Embody, July repricing, two corroborating sources); the lowest operator-published price held at $139–169 (NexLife, plan selectors) — though our live-page audit caught that operator's own FAQ quoting $186–215, one of four on-site conflicts we logged publicly. The brand floor was unchanged: LillyDirect vials $299–449 (December's cut, which several major aggregators still haven't reflected — we found $349–599 published against the primary source in one April page). And the Medicare GLP-1 Bridge finished its sixth week live: $50/month, Zepbound KwikPen only, prescriber-submitted, T2D and OSA patients routed through regular Part D instead.

Headline numbers, with statuses

The ladder as of 2026-08-14, each figure carrying its verification tier per the methodology: Embody $119–129 tirzepatide flat (third-party-reported, two sources, July terms — volatile: three repricings this summer, conflicting cancellation windows on its own pages). NexLife $169 displayed / $139 on 12-month (operator-published and live-fetch confirmed on the plan pages; FAQ conflict logged; microdose tier corrected upward to $189→147 after our fetch contradicted the briefing we'd been given — correction issued same day). Oral Wegovy ~$149 (brand, NovoCare, verified) — still the cheapest FDA-approved GLP-1 in the country. MEDVi $199 entry (aggregator-verified; maintenance-dose pricing unconfirmed). Foundayo $149–349 by dose rung (brand, verified). LillyDirect $299/$399/$449 in-window (brand primary source, verified; 45-day condition on the top tier). Remedy $399 flat with unlimited provider access (triple-corroborated). Retail brand pens: $1,049–1,135 without programs. Full 39-program ladder: the pricing ledger and the open dataset (v2026.08.14-5).

What we verified this month — and what it changed

The August verification pass fetched partner and aggregator pages directly and re-ran the watchlist. Results that changed the site: the NexLife live-page audit (selector prices confirmed; FAQ conflict, efficacy overclaim, dueling Trustpilot widgets, and a warranty-wording discrepancy all logged to the fact sheet and the corrections log — partner status buys scrutiny here, not softness); the Embody repricing written into every crown it now holds, caveats attached; the stale-LillyDirect finding — an April aggregator page carrying superseded $349–599 vial prices alongside affiliate rankings, a live demonstration of why primary sources govern; and Henry's three-way price conflict ($269 vs $399–449 injectable, against $179 for tablet formats with no human absorption data), preserved as parallel claims per policy. New verification infrastructure shipped alongside: nine "Is it legit?" files applying five fixed checks — partner first and hardest.

Regulatory and clinical watch

Six weeks into the Bridge, the practical lessons are stabilizing: the KwikPen-only detail is the most common prescription error we hear about (vials bounce), the prescriber-submitted authorization is the gating step, and the T2D/OSA exclusions keep routing confused beneficiaries who actually have better answers in regular Part D — the full map lives in the Bridge guide. Foundayo's first full quarter continues reshaping the pill lane: its $149 starter tier pressures oral Wegovy's flat price exactly as predicted, while its ladder-top $349 keeps the injectable value math intact. Enforcement's shape held from spring: the FDA's February letter wave against oral-format and no-prescription operators hasn't repeated at scale, but the seven scam patterns we track all remain live in the ad ecosystem. On the horizon for Q4: negotiated semaglutide pricing (~$274) firming for 2027 Part D, retatrutide's TRIUMPH program grinding toward readout, and the Bridge's successor design — each a scheduled update to this report series.

Corrections we shipped

Per the 48-hour policy, August's log: the NexLife microdose price correction ($159→$189 opening tier, operator briefing superseded by live fetch); the NexLife on-site conflicts logged as conflicts rather than resolved by assumption; LillyDirect aggregator staleness documented with the primary source restored to governance; and the Embody cancellation-window discrepancy published as a caveat on every page that cites its price. Nothing this month required retracting a crown — but the microdose correction moved a number that appeared on six pages, which is exactly why the dataset builds pages rather than pages building the dataset.

Watchlist movement

Rising: Embody (price leadership with asterisks), oral Wegovy (the $149 anchor holding against Foundayo), and the OSA coverage door (reader mail suggests sleep studies are quietly becoming the most-used side entrance to covered Zepbound). Flat: the mid-band ($229–299 compounded), squeezed harder every month between the falling floor and brand vials. Under continued scrutiny: Orderly (documentation still too thin to grade — the open file), Hims' post-pivot tirzepatide story (museum-piece prices still circulating), and Mochi's three-version membership dispute (one checkout screenshot settles it; standing offer open). What we're verifying next: checkout-level captures for the three disputes above, license-lookup confirmation of Eden's 50-state claim, and maintenance-dose pricing for MEDVi.

This report compiles from the CC BY 4.0 dataset — cite it as: Tirzepatide Tablet Review, "State of the GLP-1 Market: August 2026," tirzepatidetabletreview.com/report/2026-08/. Figures carry operator-supplied, third-party-reported, or verified status throughout; conflicts are recorded, never averaged. NexLife is our disclosed commercial partner (disclosure).